All In MedTech

FDA Clearance Tracker · P160030-S017

FreeStyle Libre 14 Day Flash Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 23, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 23, 2018

Approved

Time to decision

104 days

Received Apr 10, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160030-S017
Device name
FreeStyle Libre 14 Day Flash Glucose Monitoring System
Applicant location
Alameda, CA
Received
Apr 10, 2018
Decided
Jul 23, 2018
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160030

Device type

Device class
Class III

Every decision under product code PZE

FDA's approval statement

As written in FDA's record.

Approval for the FreeStyle Libre 14 Day Flash Glucose Monitoring System. The FreeStyle Libre 14 Day Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device indicated for the management of diabetes in persons age 18 and older. It is designed to replace blood glucose testing for diabetes treatment decisions. The System detects trends and tracks patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time. The System is intended for single patient use and requires a prescription.

Source documents

Other decisions for Abbott Diabetes Care, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.